The effect of nanoHHi alone or in combination with Sorafenib has been tested in HCC cell lines, and it significantly inhibited the proliferation, invasion, systemic metastasis, as well as tumor growth, of HCC and reduced the population of CD133-expressing HCC cells compared with Sorafenib treatment alone, thereby providing a new treatment regime for patients with HCC [97]. Here, PROM1 is linked to hepatocellular carcinoma.